Valsartan: a novel angiotensin type 1 receptor antagonist (Q34182288)

31 July 2017

1 reference

title

Valsartan: a novel angiotensin type 1 receptor antagonist (English)

1 reference

31 July 2017

Thürmann PA

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

1

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

337-350

1 reference

The progression from hypertension to congestive heart failure

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Binding of valsartan to mammalian angiotensin AT1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Angiotensin AT1 receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Pharmacokinetics of valsartan in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

An interaction study with cimetidine and the new angiotensin II antagonist valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

Valsartan and atenolol in patients with severe essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.2.337

21 January 2018

Identifiers

DOI

10.1517/14656566.1.2.337

1 reference

31 July 2017

1 reference